Cannabis and Δ(9)-tetrahydrocannabinol (THC) for weight loss?

“Obesity is one of the highest preventable causes of morbidity and mortality in the developed world. It has been well known for a long time that exposure to cannabis produces an increase of appetite (a phenomenon referred to as the ‘munchies’).

This phenomenon led to an exploration of the role of the endocannabinoid system in the regulation of obesity and associated metabolic syndrome. This effort subsequently led to the development of a successful therapeutic approach for obesity that consisted of blocking the cannabinoid CB(1) receptors using ligands such as Rimonabant in order to produce weight loss and improve metabolic profile. Despite being efficacious, Rimonabant was associated with increased rates of depression and anxiety and therefore removed from the market.

We recently discovered that the prevalence of obesity is paradoxically much lower in cannabis users as compared to non-users and that this difference is not accounted for by tobacco smoking status and is still present after adjusting for variables such as sex and age.

 Here, we propose that this effect is directly related to exposure to the Δ(9)-tetrahydrocannabinol (THC) present in cannabis smoke. We therefore propose the seemingly paradoxical hypothesis that THC or a THC/cannabidiol combination drug may produce weight loss and may be a useful therapeutic for the treatment of obesity and its complications.”

http://www.ncbi.nlm.nih.gov/pubmed/23410498

The future of weight loss: A ‘marijuana’ diet pill?

“Limiting a brain compound that regulates metabolism allows genetically altered mice to stay skinny without exercising. Is a dream pill far behind?

If you find the prospect of staying thin while eating as much as you want appealing, scientists have news for you. New research from the University of California, Irvine — detailed in the March issue of Cell Metabolism — found that certain brain chemicals with characteristics similar to marijuana might help the body shed pounds without any exercise. A dream come true? Here’s a brief look at the promising discovery:

What chemical could have such power?
It’s an endocannabinoid compound called 2-AG. Endocannabinoids, as the name might suggest, share a similar molecular structure to the active ingredients in cannabis. Typically, high levels of 2-AG are found in the brains of mammals, and previous studies suggested that these compounds may make the body crave fat. Scientists think endocannabinoids play a key role in regulating the body’s metabolism, or the energy it makes from food.

How did scientists put the compound to the test?
Researchers genetically engineered brain cells in mice to exhibit low levels of 2-AG, on the theory that this would allow the rodents’ metabolic rates to “go crazy,” says Kristen Philipkoski at Gizmodo. And the hunch was right. These mice lived in a “hypermetabolic state,” burning fat calories far more efficiently than normal mice, study researcher Daniele Piomeli said in a statement. They were “resistant to obesity,” staying thin despite a high-fat diet without exercise. They even had normal blood pressure, and showed no increased risk of heart disease or diabetes. 

How could this discovery help humans?
“To produce the desired effects, we would need to create a drug that blocks 2-AG production in the brain,” says Piomeli, “something we’re not yet able to do.” 

So can we expect a miracle pill in the foreseeable future?
“Tweaking” human brain chemistry is no easy task, says Philipkoski. And preliminary estimates say it would take a decade and cost up to $2 billion to make the drug safe and effective enough for the FDA to to approve it. “So don’t cancel that gym membership just yet,” says Piomeli.”

http://news.yahoo.com/future-weight-loss-marijuana-diet-pill-071500947.html

Study links pot smoking and weight loss – ABC News

“Researchers have found a surprising link between smoking marijuana and a lower risk of obesity.”

 

“Although a common side effect of cannabis is the “munchies,” the results of a French study showed about a 10 percent lower rate of obesity in people who frequently smoke marijuana compared with those who never have.

Researchers believe some components of marijuana may help people lose weight, however they emphasized that people should not smoke marijuana to lose weight.”

http://abclocal.go.com/wabc/story?section=news/health&id=8345422

The endocannabinoid system: a new target for the regulation of energy balance and metabolism.

Abstract

“Recent studies have provided evidence that the endocannabinoid (EC) system has very significant effects on energy balance and metabolism through the central control of appetite and by affecting peripheral metabolism. Endocannabinoids are endogenous phospholipid derivatives which bind and activate cannabinoid receptors type 1 and type 2 (CB1 and CB2 receptors). The CB1 receptor, a G-protein coupled receptor, is believed to be responsible for the majority of the central effects of endocannaboids on appetite. Chronic positive energy balance and obesity have been associated with an overactivation of the endocannaboid system which has been suggested to contribute to the development of abdominal obesity and to associated metabolic abnormalities which increase the risk of cardiovascular disease and type 2 diabetes. Animal studies had shown that stimulation of the cannabinoid CB1 receptor with endocannaboids such as anandamide could induce first an increase in food intake leading to body weight gain. Furthermore, an exciting development in this field has been the discovery of CB1 receptors in many peripheral tissues, including key organs involved in carbohydrate and lipid metabolism such as the adipose tissue and liver. Thus, blocking CB1 receptors located in the liver and adipose tissue could have an additional impact on the metabolic risk profile beyond what could be explained by the reduction in food intake and the related body weight loss. Preclinical studies have shown that rimonabant, the first CB1-receptor blocker to be available in clinical practice, could not only induce a reduction in food intake, but could also produce body weight loss beyond what could be explained by its effect on food intake. Thus, the evidence from preclinical studies have suggested that CB1 blockade could represent a relevant approach to reduce food intake, to induce body weight loss, and, most importantly, to “fix” the dysmetabolic state of viscerally obese patients at increased cardiometabolic risk.”

http://www.ncbi.nlm.nih.gov/pubmed/17667864